Compugen: COM701 interim ovarian data nodal catalyst set for 2027
Aug 3, 2026, 7:05 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Key catalysts (COM701 interim PFS, OS readouts from rilvegostomig, and continued Phase 1 progress) could drive upside if data meet or exceed expectations. Positive data would directly affect pipeline valuation and potential registration paths, while cash runway supports ongoing execution; negative surprises could dampen fundamentals, but near-term catalysts are the primary driver.
AI summary
What happened, with direct paths to the underlying reporting
Compugen reported Q2 2026 results, reaffirming progress across its immuno-oncology pipeline. The key catalyst is the MAIA-ovarian trial, with interim median progression-free survival data expected by 1Q2027, potentially signaling a pivotal inflection for COM701. Partnerships with AstraZeneca and Gilead advance rilvegostomig and GS-0321, while cash runway extends into 2029, supporting ongoing pipeline development.
COM701 MAIA-ovarian interim PFS data expected by 1Q2027; trial on track.
GS-0321 Phase 1 progress under Gilead license; Compugen remains cash-positioned into 2029.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
FDA clearance triggers a $30 million milestone payment from Gilead. Positive expectations for upcoming Phase 1 trial initiation. The approval positions COM503 as a first-in-class…
- Compugen reported a quarterly loss of $0.08 per share, beating estimates by 20%. - Revenues for the quarter totaled $2.56 million, missing estimates by 8.28%. - Compugen shares…
